Role of FGF23 in Pediatric Hypercalciuria

Abstract EN

Background.

This study explored the possible role of FGF23 in pediatric hypercalciuria.

Methods.

Plasma FGF23 was measured in 29 controls and 58 children and adolescents with hypercalciuria: 24 before treatment (Pre-Treated) and 34 after 6 months of treatment (Treated).

Hypercalciuric patients also measured serum PTH hormone, 25(OH)vitD, phosphate, calcium, creatinine, and 24 h urine calcium, phosphate, and creatinine.

Results.

There were no differences in age, gender, ethnicity, or body mass index either between controls and patients, or between Pre-Treated and Treated patients.

Median plasma FGF23 in controls was 72 compared with all patients, 58 RU/mL (p=0.0019).

However, whereas FGF23 in Pre-Treated patients, 73 RU/mL, was not different from controls, in Treated patients it was 50 RU/mL, significantly lower than in both controls (p<0.0001) and Pre-Treated patients (p=0.02).

In all patients, there was a correlation between FGF23 and urinary calcium (r=0.325; p=0.0014).

Treated patients had significantly lower urinary calcium (p<0.0001), higher TP/GFR (p<0.001), and higher serum phosphate (p=0.007) versus Pre-Treated patients.

Conclusions.

Pharmacological treatment of hypercalciuric patients resulted in significantly lower urinary calcium excretion, lower serum FGF23, and elevated TP/GFR and serum phosphate concentration, without significant changes in PTH.

Further studies are indicated.

This trial is registered with Clinical Registration Number RBR 8W27X5.